Category: Drugs/Drug Classes

All Podcast Categories
S4-4.4 - NASH-TAG 2023: Emerging Optimism from a Watershed Moment

S4-4.4 – NASH-TAG 2023: Emerging Optimism from a Watershed Moment

This week’s conversation series continues on the theme of reviewing NASH-TAG 2023, a watershed moment for Fatty Liver disease. For this wrap-up feature, Amy Articolo and Naim Alkhouri join Jörn Schattenberg and Roger Green to illustrate their enthusiasm coming out of the conference.

S4-4.3 - Surfing NASH Community Interview with Caitlin Schneider of Sonic Incytes

S4-4.3 – Surfing NASH Community Interview with Caitlin Schneider of Sonic Incytes

The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Caitlin Schneider (Sonic Incytes) joins Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.

S4-4.2 - Surfing NASH Community Interview with Jerry Mabary of Chronwell

S4-4.2 – Surfing NASH Community Interview with Jerry Mabary of Chronwell

The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Jerry Mabary (Chronwell) joins Roger Green to explore questions around biopsy, patient centricity, the role of digital tools and combination therapy

S4-4.1 - Surfing NASH Community Interview with Pamela Danagher of Terns Pharmaceuticals

S4-4.1 – Surfing NASH Community Interview with Pamela Danagher of Terns Pharmaceuticals

The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. In this exclusive conversation, Pamela Danagher (Terns Pharma) joins Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.

S4-4 - Surfing NASH Audience Reacts to NASH-TAG and the Future of Fatty Liver

S4-4 – Surfing NASH Audience Reacts to NASH-TAG and the Future of Fatty Liver

The podcast hosts three interviews with its longtime listeners from the Surfing NASH community to discuss their takeaways from NASH-TAG 2023 and the future of Fatty Liver. Respectively, Pamela Danagher (Terns Pharma), Jerry Mabary (Chronwell) and Caitlin Schneider (Sonic Incytes) join Jörn Schattenberg and Roger Green to explore questions around biopsy, patient centricity, NITs versus “tests” and combination therapy.

Experience Nudge Learning! Interested in a new way of learning?